PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.29 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 316.80K shares, a 92.04% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.97M shares, a 2.47% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.09M shares, a 8.82% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.29M shares, a 27.80% increase from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.79M shares, a 22.47% decline from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.31M shares, a 34.59% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 316.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 2.29M shares 10-Q · filed 2026-08-06 | 2.29M shares derived: sum of 3 quarters · filed 2026-08-06 | 2.29M shares derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | 1.97M shares 10-Q · filed 2026-05-07 | 1.97M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.97M shares derived: sum of 3 quarters · filed 2026-05-07 | 2.13M shares derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-27 | 164.96K shares derived: sum of 3 quarters · filed 2026-02-27 | 2.09M shares 10-K · filed 2026-02-27 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 164.96K shares derived: sum of 2 quarters · filed 2025-11-06 | 2.09M shares 10-Q · filed 2025-11-06 | 2.22M shares derived: sum of 4 quarters · filed 2025-11-06 | |
| 2025-06-30 | 164.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 2.09M shares 10-Q · filed 2025-08-04 | 2.22M shares derived: sum of 3 quarters · filed 2025-08-04 | 2.22M shares derived: sum of 4 quarters · filed 2025-08-04 | |
| 2025-03-31 | 1.92M shares 10-Q · filed 2025-05-08 | 2.05M shares derived: sum of 2 quarters · filed 2025-05-08 | 2.05M shares derived: sum of 3 quarters · filed 2025-05-08 | 2.21M shares derived: sum of 4 quarters · filed 2025-05-08 | |
| 2024-12-31 | 132.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 132.00K shares derived: sum of 2 quarters · filed 2025-02-27 | 289.50K shares derived: sum of 3 quarters · filed 2025-02-27 | 2.29M shares 10-K · filed 2025-02-27 | |
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-12 | 157.50K shares derived: sum of 2 quarters · filed 2024-11-12 | 2.16M shares 10-Q · filed 2024-11-12 | 2.22M shares derived: sum of 4 quarters · filed 2024-11-12 | |
| 2024-06-30 | 157.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.16M shares 10-Q · filed 2024-08-08 | 2.22M shares derived: sum of 3 quarters · filed 2024-08-08 | 2.46M shares derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | 2.00M shares 10-Q · filed 2024-05-08 | 2.06M shares derived: sum of 2 quarters · filed 2024-05-08 | 2.30M shares derived: sum of 3 quarters · filed 2024-05-08 | 2.55M shares derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-12-31 | 59.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 304.25K shares derived: sum of 2 quarters · filed 2024-02-22 | 549.45K shares derived: sum of 3 quarters · filed 2024-02-22 | 1.79M shares 10-K · filed 2024-02-22 | |
| 2023-09-30 | 245.25K shares 10-Q · filed 2023-11-02 | 490.45K shares derived: sum of 2 quarters · filed 2023-11-02 | 1.73M shares 10-Q · filed 2023-11-02 | 1.82M shares derived: sum of 4 quarters · filed 2023-11-02 | |
| 2023-06-30 | 245.20K shares 10-Q · filed 2023-08-03 | 1.49M shares 10-Q · filed 2023-08-03 | 1.58M shares derived: sum of 3 quarters · filed 2023-08-03 | 1.77M shares derived: sum of 4 quarters · filed 2023-11-02 | |
| 2023-03-31 | 1.24M shares 10-Q · filed 2023-05-04 | 1.33M shares derived: sum of 2 quarters · filed 2023-05-04 | 1.52M shares derived: sum of 3 quarters · filed 2023-11-02 | 1.81M shares derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-12-31 | 89.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 283.25K shares derived: sum of 2 quarters · filed 2023-11-02 | 567.50K shares derived: sum of 3 quarters · filed 2023-11-02 | 2.31M shares 10-K · filed 2023-02-28 | |
| 2022-09-30 | 193.50K shares 10-Q · filed 2023-11-02 | 477.75K shares derived: sum of 2 quarters · filed 2023-11-02 | 2.22M shares 10-Q · filed 2023-11-02 | 2.43M shares derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | 284.25K shares 10-Q · filed 2023-08-03 | 2.03M shares 10-Q · filed 2023-08-03 | 2.23M shares derived: sum of 3 quarters · filed 2023-08-03 | 2.41M shares derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | 1.74M shares 10-Q · filed 2023-05-04 | 1.95M shares derived: sum of 2 quarters · filed 2023-05-04 | 2.12M shares derived: sum of 3 quarters · filed 2023-05-04 | 2.72M shares derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | 207.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 383.00K shares derived: sum of 2 quarters · filed 2023-02-28 | 979.50K shares derived: sum of 3 quarters · filed 2023-02-28 | 3.53M shares 10-K · filed 2023-02-28 | |
| 2021-09-30 | 176.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 772.50K shares derived: sum of 2 quarters · filed 2021-11-04 | 3.32M shares 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | 596.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 3.15M shares 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | 2.55M shares 10-Q · filed 2021-05-11 | ||||
| 2021-02-12 | 1.37M shares 10-K · filed 2023-02-28 | ||||
| 2020-12-31 | 2.11M shares 10-K · filed 2023-02-28 | ||||
| 2019-12-31 | 1.32M shares 10-K · filed 2021-02-26 | ||||
| 2018-12-31 | 4.14M shares 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |